US FDA Publishes, Then Withdraws, PDUFA Rates Because Process ‘May Not Be Well Understood’
Executive Summary
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.
You may also be interested in...
US FDA User Fee Staffing: The Objective Capacity Planning Adjuster Often Needs Subjective Review
The FDA has overruled the results from its own formula intended to match resource levels with workload every time except once.
GDUFA III Agreement Will Constrain Fee Revenue Increases
Generic user fee program's next iteration will also offer improved mid- and post-assessment communications for sponsors to receive feedback from US FDA.
GDUFA III Agreement Will Constrain Fee Revenue Increases
Generic user fee program's next iteration will also offer improved mid- and post-assessment communications for sponsors to receive feedback from US FDA.